Does the media favor ATNM or ASRT?

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than Assertio. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for Assertio. Actinium Pharmaceuticals' average media sentiment score of 0.31 beat Assertio's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ATNM or PRQR?

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat Actinium Pharmaceuticals' score of 0.31 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNTB or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to CNTB or ATNM?

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat Actinium Pharmaceuticals' score of 0.31 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATNM or CRBP more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Corbus Pharmaceuticals N/A -70.89% -61.78%

Does the media favor ATNM or CRBP?

In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.64 beat Actinium Pharmaceuticals' score of 0.31 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HURA or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media prefer HURA or ATNM?

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than TuHURA Biosciences. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for TuHURA Biosciences. Actinium Pharmaceuticals' average media sentiment score of 0.31 beat TuHURA Biosciences' score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Actinium Pharmaceuticals (ATNM) Competitors

$1.06 -0.02 (-1.85%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$1.07 +0.01 (+1.04%)

As of 06/8/2026 06:48 PM Eastern

Compare

ATNM vs. ASRT, PRQR, CNTB, CRBP, and HURA

Should you buy Actinium Pharmaceuticals stock or one of its competitors? MarketBeat compares Actinium Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actinium Pharmaceuticals include Assertio (ASRT), ProQR Therapeutics (PRQR), Connect Biopharma (CNTB), Corbus Pharmaceuticals (CRBP), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Actinium Pharmaceuticals compare to Assertio?

Actinium Pharmaceuticals (NYSE:ATNM) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than Assertio. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for Assertio. Actinium Pharmaceuticals' average media sentiment score of 0.31 beat Assertio's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Assertio has higher revenue and earnings than Actinium Pharmaceuticals. Assertio is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	369.53	-$48.82M	-$0.75	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Assertio has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Actinium Pharmaceuticals currently has a consensus price target of $4.50, indicating a potential upside of 324.53%. Assertio has a consensus price target of $22.65, indicating a potential downside of 3.33%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Actinium Pharmaceuticals has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Assertio	-34.94%	-38.72%	-13.32%

Summary

Actinium Pharmaceuticals beats Assertio on 9 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to ProQR Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

ProQR Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	369.53	-$48.82M	-$0.75	N/A
ProQR Therapeutics	$17.99M	8.96	-$47.73M	-$0.50	N/A

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Actinium Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 324.53%. ProQR Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 373.86%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Actinium Pharmaceuticals has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat Actinium Pharmaceuticals' score of 0.31 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actinium Pharmaceuticals has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

Summary

ProQR Therapeutics beats Actinium Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Actinium Pharmaceuticals has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,308.53	-$55.48M	-$1.15	N/A
Actinium Pharmaceuticals	$90K	369.53	-$48.82M	-$0.75	N/A

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat Actinium Pharmaceuticals' score of 0.31 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Actinium Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Connect Biopharma presently has a consensus target price of $7.20, indicating a potential upside of 227.27%. Actinium Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 324.53%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Connect Biopharma has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Actinium Pharmaceuticals' return on equity of -100.85% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats Connect Biopharma on 10 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Corbus Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Corbus Pharmaceuticals' return on equity of -70.89% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market.

In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.64 beat Actinium Pharmaceuticals' score of 0.31 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actinium Pharmaceuticals has higher revenue and earnings than Corbus Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	369.53	-$48.82M	-$0.75	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

Actinium Pharmaceuticals presently has a consensus target price of $4.50, suggesting a potential upside of 324.53%. Corbus Pharmaceuticals has a consensus target price of $42.00, suggesting a potential upside of 455.56%. Given Corbus Pharmaceuticals' higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Corbus Pharmaceuticals beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than TuHURA Biosciences. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for TuHURA Biosciences. Actinium Pharmaceuticals' average media sentiment score of 0.31 beat TuHURA Biosciences' score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TuHURA Biosciences has higher earnings, but lower revenue than Actinium Pharmaceuticals. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Actinium Pharmaceuticals	$90K	369.53	-$48.82M	-$0.75	N/A

TuHURA Biosciences has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals' return on equity of -100.85% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

TuHURA Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 340.10%. Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 324.53%. Given TuHURA Biosciences' higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Actinium Pharmaceuticals beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$33.26M	$948.25M	$6.48B	$23.05B
Dividend Yield	N/A	4.84%	2.67%	4.10%
P/E Ratio	-0.76	1.47	23.69	30.30
Price / Sales	369.53	119.38	514.83	22.46
Price / Cash	N/A	20.06	26.99	18.46
Price / Book	0.81	7.84	10.43	4.61
Net Income	-$48.82M	-$4.04M	$3.57B	$1.07B
7 Day Performance	-13.82%	-1.70%	0.27%	-2.02%
1 Month Performance	-19.08%	4.38%	3.25%	-1.20%
1 Year Performance	-45.36%	105.53%	22.24%	20.56%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	3.0375 of 5 stars	$1.06 -1.9%	$4.50 +324.5%	-42.1%	$33.26M	$90K	N/A	30
ASRT Assertio	1.748 of 5 stars	$23.45 +0.1%	$22.65 -3.4%	+136.0%	$151.41M	$118.71M	N/A	20
PRQR ProQR Therapeutics	3.0667 of 5 stars	$1.47 +3.5%	$7.25 +393.2%	-19.9%	$149.61M	$17.99M	N/A	180	Positive News Gap Up High Trading Volume
CNTB Connect Biopharma	3.9446 of 5 stars	$2.15 -8.1%	$7.20 +234.9%	+178.0%	$147.34M	$60K	N/A	110	Gap Up
CRBP Corbus Pharmaceuticals	4.5256 of 5 stars	$7.54 -2.7%	$42.00 +457.0%	-18.1%	$143.59M	N/A	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. ASRT, PRQR, CNTB, CRBP, and HURA

How does Actinium Pharmaceuticals compare to Assertio?

Summary

How does Actinium Pharmaceuticals compare to ProQR Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Connect Biopharma?

Summary

How does Actinium Pharmaceuticals compare to Corbus Pharmaceuticals?

Summary

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. ASRT, PRQR, CNTB, CRBP, and HURA

How does Actinium Pharmaceuticals compare to Assertio?

Does the media favor ATNM or ASRT?

Do insiders & institutionals believe in ATNM or ASRT?

Which has better valuation and earnings, ATNM or ASRT?

Which has more risk and volatility, ATNM or ASRT?

Do analysts recommend ATNM or ASRT?

Is ATNM or ASRT more profitable?

Summary

How does Actinium Pharmaceuticals compare to ProQR Therapeutics?

Which has better earnings & valuation, ATNM or PRQR?

Do institutionals & insiders have more ownership in ATNM or PRQR?

Do analysts rate ATNM or PRQR?

Is ATNM or PRQR more profitable?

Does the media refer more to ATNM or PRQR?

Which has more risk and volatility, ATNM or PRQR?

Summary

How does Actinium Pharmaceuticals compare to Connect Biopharma?

Which has stronger valuation & earnings, CNTB or ATNM?

Does the media refer more to CNTB or ATNM?

Do institutionals & insiders believe in CNTB or ATNM?

Do analysts recommend CNTB or ATNM?

Which has more risk and volatility, CNTB or ATNM?

Is CNTB or ATNM more profitable?

Summary

How does Actinium Pharmaceuticals compare to Corbus Pharmaceuticals?

Is ATNM or CRBP more profitable?

Which has more volatility and risk, ATNM or CRBP?

Does the media favor ATNM or CRBP?

Which has preferable valuation & earnings, ATNM or CRBP?

Do analysts recommend ATNM or CRBP?

Do institutionals and insiders hold more shares of ATNM or CRBP?

Summary

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

Does the media prefer HURA or ATNM?

Which has higher earnings and valuation, HURA or ATNM?

Which has more volatility & risk, HURA or ATNM?

Do institutionals & insiders hold more shares of HURA or ATNM?

Is HURA or ATNM more profitable?

Do analysts recommend HURA or ATNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools